Power Law company profile

Sirna Therapeutics

Biotech & Life Sciences · San Francisco, United States · Founded 1992 · IPO 2006 Unicorn

Biotech company using RNA interference-based therapies to change how diseases are treated

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

6 investors on Sirna Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 6 investors entered at this stage

Oxford Bioscience Partners

Techno Venture Management

Venrock

Granite Ventures

Notable Capital

Sprout Group

Global footprint

Where Sirna Therapeutics has talent and traffic

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

Patent intelligence

$63M patent portfolio · 27 active families

Estimated portfolio value

$63M

2.7× the top peer Aprogen ($23M)

27 active patent families

Where Sirna Therapeutics innovates Nucleic acid moleculeRNA interferenceRNAGene expressionDouble stranded rna

Where Sirna Therapeutics concentrates vs peers

Each axis is a top-10 topic across Sirna Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Sirna Therapeutics

An AI-synthesized read of the highest-engagement posts about Sirna Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Sirna Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles